✦ LIBER ✦

358Early results of a large randomised trial of ‘tomudex’ (raltitrexed) versus 5-fluorouracil (5FU) plus high dose leucovorin (HDLV) in patients with advanced colorectal cancer (ACC)

✍ Scribed by J.J. McAleer; G. Cocconi; G. van Hazel; E. Francois; J.Y. Douillard; K. Possinger; D. Kerr; D. Cunningham; H. Starkhammar; T. Rugg

Book ID: 119521607
Publisher: Elsevier Science
Year: 1996
Tongue: English
Weight: 125 KB
Volume: 40
Category: Article
ISSN: 0167-8140
DOI: 10.1016/s0167-8140(96)80367-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

735 L-Leucovorin (LLV) as a modulator of

735 L-Leucovorin (LLV) as a modulator of 5-days 5-fluorouracil (5FU) in advanced colorectal cancer (ACC): High dose (HD) versus low dose (LD)

✍ R. Labianca; S. Cascinu; S. Barni; G. Fiorentini; L. Frontini; G. Comella; A. Za 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 298 KB

A phase II trial of weekly high dose con

A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer

726 - Long-term weekly treatment of adva

726 - Long-term weekly treatment of advanced colorectal cancer (CRC) with fluorouracil (5-FU) and leucovorin (LV): 5 year-results of a multicentric phase II trial of 5-FU pharmacokinetic monitoring in 152 patients

✍ B. Lamezec; C. Alleaume; E. Gamelin; M.J. Goudier; P.E. Cailleux; E. Danquechin- 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 217 KB

Phase III trial of bolus 5-fluorouracil

Phase III trial of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly oxaliplatin (OXA) plus high dose 24h 5-FU infusion/FA in patients with advanced colorectal cancer (CRC)

✍ A. Grothey; T. Buechele; H. Kroening; K. Ridwelski; P. Reichardt; A. Kretzschmar 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 163 KB

732 Modulation of weekly high dose infus

732 Modulation of weekly high dose infusional 5-fluorouracil (FU) by leucovorin (LV), α-interferon (IFN) or LV plus IFN in advanced colorectal cancer. Results of a multicenter randomized trial of the AIO

✍ C.H. Köhne; P. Schöffski; H. Wilke; C. Käufer; H. Rauschecker; R. Andreesen; U. 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Double alternate modulation of high dose

Double alternate modulation of high dose fluorouracil (5FU) by interferon alpha (IFNα) and phosphonacetyl-L-aspartic acid (pala) in patients with advanced colorectal cancer (ACC). A multicenter phase II study

✍ Punt, CJA; Burghouts, JThM; Kateman, I; Croles, JJ; Kamm, Y; De Mulder, PHM 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 160 KB